Please enable JS

ARTICLES & TESTIMONIALS

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

Pfizer Website Offers Primer on Biosimilars

Dec 26// Biosimilars

Pfizer offers a patient-friendly explanation of biosimilars – what they are, how they differ from generics, and how they are developed and approved, among other topics on the company’s biosimilars website. Read more.

READ MORE

Biosimilars Market Taking Off in the U.S.

Dec 26// Biosimilars

By 2020, the global biosimilars market is expected to top $390 billion and account for up to 28 percent of the global market for pharmaceuticals, due in large part to the loss of patent protection for commercially successful drugs. Read more.

READ MORE

GHLF’s Analysis of Current Step Therapy Regulations

Dec 26// Fail First/StepTherapy

In an analysis of step therapy regulations, GHLF looked at every state bill currently related to step therapy and scored them on how strongly they protected patients on a scale from one to 10. You can also see whether your state has passed or has pending legislation relating to step therapy protocols. Read more.

READ MORE

Are Insurance Policies Saving Patients Money, or Keeping Them from the Treatment They Need?

Dec 26// Fail First/StepTherapy

Stat News explores how insurance companies are becoming more aggressive in their reliance on step therapy, forcing patients to try cheaper treatments before they graduate to more expensive ones, even when providers say the inexpensive drugs will be ineffective. Read more.

READ MORE

Taking Specialty Prior Authorization from 5 Days to 5 Minutes

Dec 26// Prior Authorization

In a Drug Channels guest post, Scott Pribyl, CEO of SamplifyRx discusses a new scoring system called RapidPA Score™ for specialty drug prior authorizations, and examines the potential benefits of a cloud-based tool that allows for near real-time prior authorization approvals. Read more.

READ MORE

White Paper Explores the Impact of Prior Authorization on Branded Medications

Dec 26// Prior Authorization

According to one analysis, approximately 70 percent of patients encountering a prior authorization do not receive the originally prescribed medication. Frost and Sullivan have produced a white paper that offers solutions for physicians, pharmaceutical companies and pharmacists to minimize delays and inefficiencies associated with the prior authorization process. Read more.

READ MORE

Cutting the Prior Authorization Headache

Dec 26// Prior Authorization

Medical Economics explores how primary care practices can minimize the time and financial burdens associated with payers’ prior authorization requirements, from minimizing expensive imaging tests to using electronic health records. Read more.

READ MORE

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

Dec 26// PCSK9i

A study found that Repatha® (evolocumab) significantly reduced LDL cholesterol in patients with and without elevated triglycerides compared to placebo and Zetia® (ezetimibe). Learn more about the differences among LDL, HDL and triglycerides from the American Heart Association. Read more.

READ MORE

NEJM Study of Evolocumab Efficacy in Lowering LDL Cholesterol

Dec 26// PCSK9i

A study published in the New England Journal of Medicine found that Repatha® (evolocumab) reduced LDL cholesterol levels by 61 percent from pretreatment levels, and this reduction was sustained through 48 weeks. Patients taking evolocumab also showed a reduction in the rate of cardiovascular events. Learn more about the differences among LDL, HDL and triglycerides […]

READ MORE

Study Shows Safety and Efficacy of Anti-PCSK9 Antibodies in Lowering LDL Cholesterol

Dec 26// PCSK9i

A study published in BMC Medicine found that the anti-PCSK9 antibodies Repatha® (evolocumab) and Praluent® (alirocumab) reduced the LDL (bad) cholesterol level by over 50 percent, increased the HDL (good) cholesterol level, and resulted in favorable changes in other lipids. As some patients cannot tolerate statins, there is a need for alternative treatments that lower […]

READ MORE